



# TIBCS 2024

Taipei International Breast Cancer Symposium

— Right Choice for Right Patient —

October 26 (SAT.) ▶ 27 (SUN.) , 2024

7F, Taipei Nangang Exhibition Center, Hall 2

10.26 (Sat.)

Room 701A

TIME	TOPIC	SPEAKER	MODERATOR
08:30-09:00	Opening Remarks	Shou-Tung Chen	
<b>Special Lecture</b>			
09:00-09:30	Global International-Initiated Trial (PATHWAY Trial) in Asian Countries for HR-Positive/HER2-Negative Advanced Breast Cancer	Kenji Tamura	King-Jen Chang
<b>Diversity of Triple Negative Breast Cancer and the Role of Immunotherapy</b>			
09:30-10:00	Are All Triple Negative Breast Cancers the Same?	Jorge S. Reis-Filho	Cheng-Ping Yu
10:00-10:30	Current Status and Future Prospects of Immunotherapy in Breast Cancer Treatment, Past, Present, and Future	Tan Jing Ying Tira	Ching-Hung Lin
<b>Coffee Break</b>			
10:30-10:50	Precision Immunotherapy for TNBC, from Clinical Factors to Tumor Microenvironment	Giampaolo Bianchini	Hsien-Kun Chang
11:20-11:50	From Consistent 1L CDK4/6i Evidence Based Survival Benefit to Real World Clinical Practice in HR+HER2 mBC	Shih-Yu Huang	Kuo-Ting Lee
11:50-12:10	Panel Discussion	Jorge S. Reis-Filho Tan Jing Ying Tira Giampaolo Bianchini Shih-Yu Huang	Ming-Feng Hou Takashi Ishikawa
12:10-12:50	Luncheon Symposium (1) Docetaxel, Aging Like a Fine Wine	Chun-Yu Liu	Liang-Chih Liu
<b>Coffee Break</b>			
<b>Advance in the Management of Luminal Disease</b>			
13:10-13:40	The Sustainable Efficacy of CDK4/6 Inhibitor Therapy in HR+/Her2- Node+ High Risk Early Breast Cancer	Nadia Harbeck	Dar-Ren Chen
13:40-14:10	Adjuvant Treatment for Young Age ER+ Early Breast Cancer (EBC)	Prudence Francis	Shyr-Ming Sheen-Chen
14:10-14:40	Bridging Treatment Gaps for Stage II and III HR+/HER2- Early Breast Cancer with CDK4/6 Inhibitors	Stephen Chia	Fang-Ming Chen
<b>Coffee Break</b>			
15:00-15:30	Long-Term Survival Benefits of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer: Insights from Real-World Evidence	Hope S. Rugo	Fiona Tsui-Fen Cheng
15:30-16:00	Novel Strategies to Overcome Resistance to Endocrine Therapy in HR+ aBC: From Biological Perspectives to Clinical Advances	Javier Cortés	Tsu-Yi Chao
16:00-16:20	Panel Discussion	Prudence Francis Stephen Chia Hope S. Rugo Javier Cortés	Shin-Cheh Chen Shinji Ohno
<b>Antibody-Drug-Conjugate: Innovations and Future Directions</b>			
16:20-16:50	Navigating ADC to Clinical Success with the Learning from Current Research	Leif Ellisen	Chiun-Sheng Huang
16:50-17:20	Riding the Wave of Innovation: The Evolving Landscape of ADCs in Breast Cancer Treatment	Paolo Tarantino	Jiun-I Lai
17:20-17:50	Optimizing Survival: Individualized Adjuvant Strategies for Maximizing Neoadjuvant Benefits	Sibylle Loibl	Ling-Ming Tseng
17:50-18:10	Panel Discussion	Leif Ellisen Paolo Tarantino Sibylle Loibl	Yen-Shen Lu



## 台北國際乳癌研討會





# TIBCS 2024

Taipei International Breast Cancer Symposium

— Right Choice for Right Patient —

October 26 (SAT.) ▶ 27 (SUN.) , 2024

7F, Taipei Nangang Exhibition Center, Hall 2

10.27 (Sun.)

Room 701A

TIME	TOPIC	SPEAKER	MODERATOR
<b>Breakfast Symposium</b>			
08:20-08:50	The Current Role of Combination Chemotherapy in Metastatic Breast Cancer Treatment	Ta-Chung Chao	Nei-Min Chu
<b>Locoregional Treatment</b>			
08:50-09:20	Axillary Surgery in Clinically Node Negative and Positive Disease: Current Indication	Jai Min Ryu	Yao-Jen Chang
09:20-10:00	Current Topics in Breast Cancer Radiation Oncology: Axillary Management, Multi-Centric Disease, and Second Breast-Conserving Therapy	Philip Poortmans	Jyh-Cherng Yu
10:00-10:30	How to Avoid Axillary Dissection in Breast Cancer Patients with Metastatic Axillary Lymph Nodes on Preoperative Ultrasound?	Jana de Boniface	Chao-Ming Hung
10:30-10:50	Panel Discussion	Jai Min Ryu Philip Poortmans Jana de Boniface	Guo-Shiou Liao Wonshik Han
10:50-11:10	<b>Coffee Break</b>		
<b>Manipulating Estrogen Receptor Positive Cancer Cell: From Molecular Insights to Clinical Practices</b>			
11:10-11:40	Breast Cancer Biology for Precision Medicine	Christos Sotiriou	Wen-Hung Kuo
11:40-12:10	Diagnostic and Therapeutic Considerations in Tumor Microenvironments	Mark Pegram	Chi-Cheng Huang
<b>Concerning Not Only About Cancer</b>			
12:10-12:50	<b>Luncheon Symposium (2)</b> Real World Evidence: Astragalus Polysaccharides Injection and Breast Cancer Patients with Cancer-Related Fatigue	Ming-Shen Dai	Kun-Ming Rau
12:50-13:10	<b>Coffee Break</b>		
13:10-13:40	Unmet Needs in Early Stage HER2 Positive Breast Cancer: the Benefit of Extended Adjuvant Treatment	Hsu-Huan Chou	Shih-Che Shen
13:40-14:10	Cardio-Oncology: Protecting the Heart as Curative Breast Cancer Treatment	Wei-Ting Chang	Hsien-Tang Yeh
14:10-14:40	Navigating the Intersection of Breast Cancer and Bone Health: the Role of Denosumab in Preventing Skeletal-Related Events	Li-Kun Ko	Chin-Yao Lin
14:40-15:00	<b>Coffee Break</b>		
<b>From Translational Research to Clinical Practice: The Role of TIL Assessment in Clinical Action</b>			
15:00-15:30	Potential Role of TIL Assessment in Clinical Practice?	Sherene Loi	Chen-Hsiang Chang
15:30-16:00	TNBC	Yuan-Ching Chang	Shou-Tung Chen
	ER+	Dwan-Ying Chang	
	HER2+	Wei-Pang Chung	
16:00-16:20	Award Ceremony   Closing Remarks		Shou-Tung Chen



## 台北國際乳癌研討會





# TIBCS 2024

Taipei International Breast Cancer Symposium

— Right Choice for Right Patient —

October 26(SAT.) ▶ 27(SUN.) ,2024

7F, Taipei Nangang Exhibition Center, Hall 2

10.26 (Sat.)

Room 701B

TIME	TOPIC	SPEAKER	MODERATOR
<b>TBCS-GBCC Joint Session: When EAST meets WEST</b>			
10:30-10:50	Screening, Diagnosis and Surveillance Between East and West	Eun Sook Ko	
10:50-11:10	Difference in Surgical Considerations and Oncoplastic Surgery Between East and West	Wen-Ling Kuo	
11:10-11:30	Difference in Medical Considerations and Survivorship Between East and West	Hyun Jo Youn	Ming-Yang Wang Hee Jeong Kim
11:30-12:00	Panel Discussion What Are the Unique Surgical Needs in Asian Population and How to Meet Them?	Eun Sook Ko Wen-Ling Kuo Hyun Jo Youn Yoo-Soek Kim Chih-Chiang Hung	
12:10-12:50	Please Proceed to Room 701A for the Lunch Symposium		

10.26 (Sat.)

Room 701B

TIME	TOPIC	SPEAKER	MODERATOR
<b>Young Doctors Forum &amp; Young Doctors Debate</b>			
<b>Young Doctors Forum (YDF)</b>			
13:00-13:05	Opening Remarks	Chi-Cheng Huang	
13:05-13:30	How to Ask Translational Questions?	Shiuan Chen	
13:30-13:55	Agonies of Young Doctors within the South Korean Health Care System	Junwon Min	
13:55-14:00	Q & A	ALL	
14:00-14:05	Break		
<b>Young Doctors Debate (YDD)</b>			
14:05-14:45	Should ALND be Performed in ypN1micro Luminal Breast Cancer Patient with Initial cN1 After Neoadjuvant Chemotherapy?	YDF Invitees	Wen-Ling Kuo
14:45-15:25	Should Adjuvant Pembrolizumab be Considered in Early TNBC Patients Achieving pCR After Neoadjuvant Chemotherapy Combined with Immunotherapy?		Chun-Yu Liu
15:25-15:30	QA & Closing Remarks	Jeong Eon Lee	
	Group Photo	ALL	



## 台北國際乳癌研討會





# TIBCS 2024

Taipei International Breast Cancer Symposium

— Right Choice for Right Patient —

October 26 (SAT.) ▶ 27 (SUN.), 2024

7F, Taipei Nangang Exhibition Center, Hall 2

10.26 (Sat.)

Room 702

TIME	#	TOPIC	PRESENTER
<b>Oral Presentation</b>			
10:50-11:00	1	Collagen Family Proteins, Thrombospondin 1 and Lumican are Differentially Expressed Across Breast Cancer Subtypes by Functional Proteomics: a Preliminary Study with Bioinformatics Analysis	Chi-Cheng Huang
11:00-11:10	2	Integrative Omics Analysis Reveals DTX1 as a Key Marker and Drug Target in Breast Cancer	Yen-Dun Tzeng
11:10-11:20	3	Therapeutic Co-Targeting of the BTK/HER2 Axis Induces Iron Accumulation to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer	Chih-Ming Su
11:20-11:30	4	ATP Synthasome Contributes to Efficient Energy Flux in Malignant Breast Cancer	Chia-Jung Li
11:30-11:40	5	The Application of a PI3K Inhibitor and an AKT Inhibitor in HER2-positive Breast Cancer Cells with Resistance to HER2-directed Antibody-drug Conjugates	Wei-Pang Chung
11:40-11:50	6	Targeting the USP7-CDK1 Axis Suppresses Estrogen Receptor-positive Breast Cancer Progression	Joseph Lin
11:50-12:00	7	SLC6A14-Mediated Glutamine Metabolism Reprogramming Enhances Cancer Stemness for Early Onset of Breast Cancer	Meng-Xia Su
12:00-12:10	8	Discovery and Biological Evaluation of a Novel Inhibitor for Human Breast Cancer Treatment	Cheng-Chiao Huang
12:10-12:20	9	Enhancing the Detection of Contralateral Breast Cancer in Breast Cancer Survivors Using Artificial Intelligenc	Jijung Jung
12:20-12:30	10	Pattern of Failure and Timing of Progression on CDK4/6 Inhibitor as First Line Therapy for HR+HER2- Metastatic Breast Cancer Invading Different Organ	Ruoh-Yun Gau
12:30-13:30	Lunch & Coffee Break		
13:10-13:20	11	Prognostic Effects of ABCB1 and TMEM14B Expression in Triple-negative Breast Cancer	Sin-Hua Moi
13:20-13:30	12	Co-targeting PD-L1 and CDK4 Benefits Plasticizer-associated Early-onset Breast Cancer	Shu-Wei Hu
13:30-13:40	13	Mechanistic Insights into Melittin's Efficacy Against Tamoxifen-Resistant Breast Cancer: Apoptosis, Proliferation, and Migration Modulation	Min-Hua Wu
13:40-13:50	14	LOC100506691, a Long Noncoding RNA, Acts as Novel Oncogene in Regulating Breast Cancer Growth	Kian Hwee Chong
13:50-14:00	15	Molecular Characterization of HER2 Low Breast Cancers Reveals a Biologically and Clinically Distinct Entity with Heterozygous Loss of ERBB2	Xintao Qiu
14:00-14:10	16	Using Bilateral Thoracoabdominal Flaps for Extensive Defects After Bilateral Mastectomy for Inflammatory Breast Cancer	Ryohei Katsuragi
14:10-14:20	17	Case Report of Stereotactic Body Radiation Therapy for Oligometastatic Breast Cancer Patient	Masahiro Yoshida
14:20-14:30	18	ExoLinc-p21s: a Short LincRNA-p21-engineered Exosome as a Chemosensitizer for Targeting DDB2-mediated DNA Repair	Yu-Hao He
14:30-14:40	19	LXPB5268 Combined with Neoadjuvant Chemotherapy in early-stage Triple-Negative Breast Cancer Patients	Chin-Yin Kuo
14:40-15:00	Coffee Break		
15:00-15:10	20	Multi-omics and Spatial Transcriptomics Unveil the Role of Ferroptosis Suppressor FANCD2 in Clinicopathology and Predicting Immunotherapy Response in Breast Cancer	Hung-Yu Lin
15:10-15:20	21	Combination of Endocrine Therapy, Gonadotropin-releasing Hormone Agonist, and Immunotherapy Enhance immune Activation in Premenopausal ER+/HER2- Metastatic Breast Cancer Patients: Final Updates from PEER Study	I-Chun Chen
15:20-15:30	22	Circulating CD3+CD8+ T Lymphocytes as Indicators of Disease Status in Patients with Early Breast Cancer	Hui-Ping Hsu



## 台北國際乳癌研討會

